Wells Fargo’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-400
| Closed | -$2.01K | – | 7316 |
|
|
2024
Q3 | $2.01K | Sell |
400
-9
| -2% | -$58 | ﹤0.01% | 6057 |
|
|
2024
Q2 | $2.7K | Sell |
409
-770
| -65% | -$5.24K | ﹤0.01% | 5974 |
|
|
2024
Q1 | $13K | Buy |
1,179
+363
| +44% | +$3.93K | ﹤0.01% | 5691 |
|
|
2023
Q4 | $11K | Buy |
816
+1
| +0.1% | +$16 | ﹤0.01% | 5814 |
|
|
2023
Q3 | $17.7K | Buy |
815
+421
| +107% | +$13.5K | ﹤0.01% | 5647 |
|
|
2023
Q2 | $15.2K | Sell |
394
-2
| -0.5% | -$71 | ﹤0.01% | 5814 |
|
|
2023
Q1 | $11K | Buy |
396
+242
| +157% | +$8.21K | ﹤0.01% | 5837 |
|
|
2022
Q4 | $5.07K | Sell |
154
-6
| -4% | -$438 | ﹤0.01% | 5769 |
|
|
2022
Q3 | $19K | Hold |
160
| – | – | ﹤0.01% | 5441 |
|
|
2022
Q2 | $28K | Sell |
160
-19
| -11% | -$4.01K | ﹤0.01% | 5291 |
|
|
2022
Q1 | $52K | Sell |
179
-76
| -30% | -$28.8K | ﹤0.01% | 5643 |
|
|
2021
Q4 | $134K | Buy |
255
+104
| +69% | +$74.6K | ﹤0.01% | 5487 |
|
|
2021
Q3 | $57K | Buy |
151
+21
| +16% | +$9K | ﹤0.01% | 5580 |
|
|
2021
Q2 | $116K | Buy |
130
+10
| +8% | +$7.65K | ﹤0.01% | 5249 |
|
|
2021
Q1 | $143K | Sell |
120
-321
| -73% | -$443K | ﹤0.01% | 5321 |
|
|
2020
Q4 | $586K | Sell |
441
-1,185
| -73% | -$1.74M | ﹤0.01% | 4414 |
|
|
2020
Q3 | $3.67M | Sell |
1,626
-105
| -6% | -$237K | ﹤0.01% | 2793 |
|
|
2020
Q2 | $3.9M | Buy |
+1,731
| New | +$4.71M | ﹤0.01% | 2713 |
|
Wells Fargo's BIOR Position: Q4 2024 in Review
Wells Fargo sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 400 shares — an estimated $2.01K sold.
Wells Fargo first reported a position in BIOR in Q2 2020 and held it in 18 quarters. The position peaked at $3.9M in Q2 2020. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- Wells Fargo reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Wells Fargo sold 400 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $2.01K.
- Wells Fargo first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- Wells Fargo's Biora Therapeutics, Inc. Common Stock position peaked at $3.9M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.